HighSTEACS is a randomised controlled trial, across 10 hospitals in NHS Lothian and NHS Greater Glasgow & Clyde, assessing patient outcomes before and after the implementation of high sensitivity Troponin assay
EMERGE Research team
Cardiology Research Group
HighSTEACS is a randomised controlled trial, across 10 hospitals in NHS Lothian and NHS Greater Glasgow & Clyde, assessing patient outcomes before and after the implementation of high sensitivity Troponin assay. The primary endpoint is the one-year rate of cardiovascular death or recurrent myocardial infarction. Secondary endpoints include length of stay, unplanned coronary revascularisation, recurrent hospital admissions excluding ACS, bleeding events and non-cardiovascular death. There is also a sub-study at the ED, RIE and in one site in NHS Greater Glasgow and Clyde.
Prospective stepped wedge cluster randomised controlled trial
Patients who present to the Emergency Department with suspected heart disease
This trial is a two arm, multicentre parallel group, randomised controlled, open label trial comparing intravenous levetiracetam to intravenous phenytoin for the treatment of convulsive status epilepticus (CSE) in children, young people and young adults.
Emergency Treatment with Levetiracetam or Phenytoin in Status Epilepticus in Children (EcLiPSE) – an open label randomised controlled trial
The Emergency Medicine Annotated Bioresource Consortium (EM-ABC): A pilot and feasability programme
Developing a bioresource for all emergency presentations
1. Ambulatory Device, Rocket Pleural vent insertion
2. Standard Treatment, Aspiration +/- chest drain
Primary Outcome Measures
To assess whether use of an ambulatory device (Rocket Pleural Vent) and treatment strategy reduces hospital stay. Total length of stay in hospital up to 30 days post randomisation. Up to 30 days post randomisation.
RAMPP trial - Randomised Controlled Trial: Pleural vent (rocket) V standard care in Primary Spontaneous Pnuemothorax